Souhaitez-vous accéder aux communiqués récents ?

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 Teclistamab monotherapy delivered superior progression-free...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall...

Atos Group Full Year 2025 Results

Edinburgh, UK, March 05, 2026 (GLOBE NEWSWIRE) -- PartnerBridge, the partner discovery and activation platform, today announced a string of milestones demonstrating its growing traction and market...

Solid 2025 resultsDebt reduction trajectory confirmedGrowth objectives for 2025-2028 All tables are available in the PDF.   Successful plan to strengthen the financial position and confirmed debt...

Platform focus yields highest ever quarter revenues and adjusted EBITDA In 2025, Azerion focused on its Platform business, introduced Azerion Intelligence (our multi-cloud and AI platform),...

Dublin, Feb. 25, 2026 (GLOBE NEWSWIRE) -- The "Effective Management of Supply Chain Risk Training Course (June 8th - June 9th, 2026)" training has been added to ResearchAndMarkets.com's offering. ...

The year 2025 in the TextMagic Group was characterised by several strategic decisions aimed at improving performance and operational efficiency in future periods. During the year, structural changes...

Subcutaneous (SC) amivantamab reduces administration from hours to minutes, with efficacy and safety consistent with intravenous (IV) amivantamab1,2,3,4,5 SC amivantamab is now authorised across all...

2025 annual results Strong operational performancePositive cash flow, reducing net financial debt Performance supported by the highest nuclear power output in France in 6 years Electricity output:...